ALKERMES APPOINTS DR. NANCY SNYDERMAN

 

Alkermes Appoints Nancy Snyderman, M.D., to Board of Directors

May 26, 2016 07:00 AM Eastern Daylight Time

DUBLIN–(BUSINESS WIRE)–Alkermes plc (NASDAQ: ALKS) today announced the appointment of Nancy L. Snyderman, M.D., to the company’s Board of Directors. Dr. Snyderman most recently served as Chief Medical Editor at NBC News, and has more than three decades of experience as a leading voice in healthcare and medicine. Dr. Snyderman is a board certified Otolaryngologist-Head and Neck Surgeon and Fellow in the American College of Surgeons.

We are delighted to welcome Nancy to our Board of Directors. She has exceptional insights from her range of experiences as a surgeon, medical journalist and advisor to major organizations, and will bring a unique and valuablE perspective to Alkermes,” said Richard Pops, Chief Executive Officer of Alkermes. Nancy has a deep understanding of the value of medical innovation as well as the barriers that must be overcome in order to bring it to physicians, patients and communities. She will be a key strategic advisor as our products and pipeline are beginning to have a greater impact in the evolving healthcare ecosystem.”

“I am delighted to join Alkermes’ Board of Directors at a time when the company is clearly beginning to have an important impact on critical diseases of our time, including addiction and schizophrenia,” said Dr. Snyderman. “I look forward to applying the insights that I have acquired through my years of experience working within many realms of the medical community, and contributing to the achievement of Alkermes’ mission to advance innovative medicines and help patients and their families.”

About Alkermes

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio.

For more information, please visit Alkermes’ website at www.alkermes.com.

 

Posted in News Release.